Yes, solriamfetol can be used to treat excessive daytime sleepiness in patients with obstructive sleep apnea.
Solriamfetol is FDA-approved and strongly recommended for treating excessive daytime sleepiness (EDS) associated with obstructive sleep apnea (OSA). 1
FDA Approval and Mechanism
Solriamfetol (SUNOSI) is FDA-approved specifically for improving wakefulness in adults with EDS associated with OSA 1. It works as a dopamine and norepinephrine reuptake inhibitor (DNRI), though the exact mechanism for improving wakefulness remains unclear 1. The medication is a Schedule IV controlled substance due to potential for abuse or dependency 1.
Clinical Evidence and Efficacy
The American Academy of Sleep Medicine (AASM) 2021 guideline provides a STRONG recommendation for using solriamfetol to treat narcolepsy, with high-quality evidence demonstrating clinically significant improvements in excessive daytime sleepiness and disease severity 2. While this guideline specifically addresses narcolepsy, the evidence base for OSA is equally robust.
Multiple high-quality randomized controlled trials demonstrate:
- Significant improvement in objective sleepiness: Solriamfetol significantly increased mean sleep latency on the Maintenance of Wakefulness Test (MWT) by approximately 10-12 minutes compared to placebo at week 12 3, 4
- Significant reduction in subjective sleepiness: Epworth Sleepiness Scale (ESS) scores decreased by 2-4.6 points more than placebo 3, 4
- Clinical response rates: 51.8%-73.0% of OSA patients achieved normal ESS scores (≤10), and 50.0%-81.9% achieved ≥25% reduction in ESS scores, compared to 37.7% and 36.8% with placebo, respectively 5
- Efficacy regardless of OSA severity: Benefits were demonstrated across all apnea-hypopnea index (AHI) subgroups, including those with AHI <5-30, and ≥30 4
Critical Clinical Context: Not a Substitute for Primary OSA Therapy
Solriamfetol treats the symptom of sleepiness but does NOT treat the underlying airway obstruction in OSA 1. Patients must continue using their primary OSA therapy (CPAP, oral appliances, etc.) as prescribed. The medication is not a substitute for treating the actual sleep-disordered breathing 1.
Dosing and Administration
- Starting dose: 37.5 mg once daily upon awakening 1
- Titration: May increase to 75 mg after at least 3 days, then to 150 mg (maximum dose for OSA) after at least 3 days if needed 1
- Timing: Take upon awakening; avoid within 9 hours of planned bedtime to prevent insomnia 1
- Food: Can be taken with or without food (food delays absorption by ~1 hour but doesn't affect overall exposure) 1
When to Consider Solriamfetol in OSA Patients
Based on the 2026 Chinese OSA guidelines and clinical evidence, solriamfetol should be considered for 6:
- Residual EDS despite adequate and adherent standard OSA therapy (CPAP, oral appliances, surgery) with other causes of EDS excluded
- EDS in patients who refuse, are intolerant of, or nonadherent to standard OSA therapy
- EDS that substantially impairs quality of life, work/study performance, or significantly increases risk of traffic/occupational accidents
The 2026 Chinese guidelines specifically state: "For patients with residual EDS despite adequate and adherent OSA therapy, treatment with solriamfetol or modafinil is recommended to improve daytime sleepiness (1, A). For patients with EDS who refuse or cannot tolerate standard OSA therapy, individualized treatment with solriamfetol is recommended (1, A)" 6.
Safety Profile
Common adverse events (generally mild to moderate) include 2, 1, 3:
- Headache
- Decreased appetite
- Insomnia
- Nausea
- Dizziness
- Dry mouth
- Anxiety
- Upper respiratory tract infection
- Hypertension
- Hyperuricemia
Critical safety considerations:
- Blood pressure and heart rate: Solriamfetol increases both; monitor regularly 1. Mean heart rate increases of 21-27 bpm were observed in studies 1
- Psychiatric symptoms: Monitor for anxiety, insomnia, irritability, agitation, psychosis, or bipolar symptoms 1
- Pregnancy: May cause fetal harm based on animal data; human data insufficient 2, 1
- Breastfeeding: Passes into breast milk; monitor infants for agitation, insomnia, and reduced weight 1
- Renal impairment: Dose adjustment required (not detailed in provided evidence, but mentioned) 1
- Drug interactions: Avoid with MAOIs (within 14 days) 1
Long-Term Efficacy and Adherence to Primary Therapy
Importantly, solriamfetol does not negatively affect adherence to primary OSA therapy 7. In a long-term study, CPAP use remained stable (90% of nights, 6.6 hours/night at baseline vs. minimal changes at week 40) while patients were on solriamfetol 7. Long-term efficacy was maintained for up to 52 weeks with no new safety concerns 8.
Impact on Sleep Quality
Solriamfetol does not significantly disrupt nocturnal sleep architecture or quality 9. No clinically significant changes were observed in total sleep time, wake after sleep onset, sleep stages, or AHI when taken in the morning 9.
Comparison to Other Wake-Promoting Agents
While the 2026 shift work disorder guidelines discuss armodafinil and modafinil as FDA-approved for shift work disorder 10, and the 2013 ACP OSA guideline found insufficient evidence for pharmacologic agents in OSA 11, the evidence base has evolved significantly since then. Solriamfetol now has robust, high-quality evidence specifically for OSA-related EDS that was not available when older guidelines were written.
Common Pitfalls to Avoid
- Do not use solriamfetol as monotherapy for OSA: Always ensure primary OSA therapy is optimized first
- Do not prescribe without screening for other causes of EDS: Rule out insufficient sleep, other sleep disorders, medications, medical/psychiatric conditions
- Do not take too close to bedtime: Maintain 9-hour window before planned sleep
- Do not ignore cardiovascular monitoring: Regular BP and HR checks are essential
- Do not assume it will improve CPAP adherence: While it doesn't worsen adherence, it's not a strategy to improve it